Body fat distribution and body composition during GnRH agonist therapy

Area of Science:

• Endocrinology
• Metabolic Health
• Women's Health

Background:

• Gonadotropin-releasing hormone (GnRH) agonists are used to treat conditions like uterine leiomyomas.
• Understanding the systemic effects of GnRH agonist therapy on body composition is crucial for patient management.

Purpose of the Study:

• To evaluate the impact of GnRH agonist therapy on body composition, including lean mass, fat mass, and fat distribution.
• To assess changes in bone mineral density and uterine volume during treatment.

Main Methods:

• A prospective study involving 15 women with uterine leiomyomas treated with a GnRH agonist (leuprorelin acetate).
• Body composition, fat distribution (trunk-leg fat ratio), bone mineral density, and uterine volume were assessed using dual-energy x-ray absorptiometry and ultrasonography before and after 4 months of therapy.

Main Results:

• Significant decreases in total body, trunk, and leg lean mass were observed.
• Significant increases in total body fat mass, percentage of body fat, and trunk fat mass occurred.
• The trunk-leg fat ratio increased, indicating a shift towards upper body fat accumulation. Bone mineral density and uterine volume also decreased significantly.

Conclusions:

• GnRH agonist therapy induces hypogonadism, leading to lean mass reduction and increased overall adiposity.
• The therapy promotes a redistribution of fat towards the upper body (trunk).
• Therapeutic strategies should consider the potential for lean mass loss, increased fat mass, and decreased bone mineral density.